Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gonalef filed for female infertility in Japan

This article was originally published in Scrip

Executive Summary

Merck Seronohas submitted an approval application in Japan for the recombinant human follicle-stimulating hormone product Gonalef (follitropin alfa) for the additional indication of induction of ovulation in infertile women. The filing includes data from a local Phase III study in women with no or irregular ovulation or polycystic ovary syndrome. Gonalef (also marketed elsewhere as Gonal-f) was first launched in Japan in 2006 for infertility in men with hypogonadotropic hypogonadism, for which it is used in combination with human chorionic gonadotropin.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts